Αρχική World News Daraxonrasib Shows Antitumour Activity Among Patients with Previously Treated RAS-mutated Pancreatic Ductal... World News Daraxonrasib Shows Antitumour Activity Among Patients with Previously Treated RAS-mutated Pancreatic Ductal Adenocarcinoma Από Ogkologos - 14 Μαΐου, 2026 333 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the RMC-6236-001 study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR Toripalimab Becomes First Immunotherapy Drug Approved for Nasopharyngeal Cancer 3 Ιανουαρίου, 2024 Nurse Diagnosed with Stage IV Cancer After Thinking Her Pain Was... 23 Μαρτίου, 2021 FDA Grants Accelerated Approval to Lifileucel for Unresectable or Metastatic Melanoma 28 Φεβρουαρίου, 2024 Cancer Research UK thanks Tania Bryer for a decade of fundraising... 19 Απριλίου, 2022 Φόρτωση περισσοτέρων HOT NEWS EMA Recommends Extension of Therapeutic Indications for Daratumumab A Combination of Talazoparib and Enzalutamide Prolongs OS in Unselected and... De qué manera el seguimiento de los síntomas mejora la atención... Utility of Serial ctDNA in Guiding Anti-EGFR Rechallenge in Metastatic Colorectal...